Post Menopausal Osteoporosis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Post Menopausal Osteoporosis – Drugs In Development, 2023’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis
- The report reviews pipeline therapeutics for Post Menopausal Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Post Menopausal Osteoporosis therapeutics and enlists all their major and minor projects
- The report assesses Post Menopausal Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Ablynx NVAddpharma Inc
Airsea (Taizhou) Pharmaceutical Ltd
AlphaMab Co Ltd
Alvotech SA
Amgen Inc
Aryogen Pharmed Co
Aurobindo Pharma Ltd
Beijing Health Guard Biotechnology Inc
Beijing Northland Biotech Co Ltd
Biocon Ltd
Celltrion Inc
Clayton Biotechnologies Inc
Clonz Biotech Pvt Ltd
CSPC Pharmaceutical Group Ltd
Dongkook Pharmaceutical Co Ltd
Eden Biologics Inc
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Epygen Biotech Pvt Ltd
Fresenius Kabi SwissBioSim GmbH
Gedeon Richter Plc
Genor BioPharma Co Ltd
Hualan Biological Engineering Inc
Ipsen SA
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabxience Holding SL
Monash University
Nano Intelligent Biomedical Engineering Corp
Nanomedic Inc
NeuClone Pty Ltd
Paras Biopharmaceuticals Finland Oy
Radius Health Inc
Reliance Life Sciences Pvt Ltd
Samsung Bioepis Co Ltd
Sandoz Group AG
Shandong New Time Pharmaceutical Co Ltd
Shanghai Braegen Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shenzhen Salubris Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
Transcenta Holding Ltd
Uni-Bio Science Group Ltd
Univeristy of Zaragoza
University of Montpellier
Wuxi Hebang Biotechnology Co Ltd